

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Joji Nakayama, Representative Director, President and CEO  
(Code no.: 4568, First Section, Tokyo Stock Exchange)  
Please address inquiries to Noriaki Ishida Corporate Officer,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com>

### **Daiichi Sankyo, Inc. Announced Civil Settlement**

**TOKYO, Japan (January 13, 2015)** – Attached is a press release by Daiichi Sankyo, Inc., a subsidiary of Daiichi Sankyo Co., Ltd. announced on January 9 in the US, 2015 that it has reached a civil settlement with the U.S. Government.

## **Daiichi Sankyo, Inc. Announces Civil Settlement**

**Parsippany, NJ – January 9, 2015** – Daiichi Sankyo, Inc. (“the Company”) announced today that it has reached a civil settlement with the U.S. Government, as well as participating states to conclude a Federal investigation related to certain types of speaker programs related to Azor, Benicar, Benicar HCT, Welchol and Tribenzor.

Under the agreement, the Company has agreed to pay approximately \$39 million, plus fees and costs, and has entered into a Corporate Integrity Agreement with the Office of Inspector General for the U.S. Department of Health and Human Services.

The settlement involves claims regarding Physician Opinion & Discussion programs during the period from January 1, 2005, through March 31, 2011, and other speaker programs during the period from January 1, 2004, through February 4, 2011.

“We are pleased to have finalized these agreements and remain focused on our core mission of helping people live healthy and meaningful lives,” said Ken Keller, President, U.S. Commercial, Daiichi Sankyo, Inc. “We are committed to being an ethical, trusted and respected company, and constantly improving how we operate is part of our culture. As part of our compliance program, we continue to review and strengthen our policies, procedures and processes to ensure compliance with applicable laws, regulations and industry standards, and to meet our own high ethical standards.”

Daiichi Sankyo, Inc. cooperated with investigators at all times throughout the investigative process.

### **About Daiichi Sankyo**

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a “Hybrid Business Model,” which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: [www.daiichisankyo.com](http://www.daiichisankyo.com).

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit [www.dsi.com](http://www.dsi.com).

Kimberly Wix  
Daiichi Sankyo, Inc.  
[kwix@dsi.com](mailto:kwix@dsi.com)  
(973) 944-2338